CCPA

CCPA (2-Chloro-N6-cyclopentyladenosine) a highly selective A1 adenosine receptors agonist with a Ki of 0.4 nM. CCPA selectively binds to adenosine A1 over adenosine A2 receptors (Ki of 3900 nM) . CCPA is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1][2][3].

Product Specifications

CAS Number

[37739-05-2]

Product Name Alternative

2-Chloro-N6-cyclopentyladenosine

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Adenosine Receptor; Apoptosis; Nucleoside Antimetabolite/Analog

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; GPCR/G Protein

Applications

Cancer-programmed cell death

Field of Research

Cancer; Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/ccpa.html

Purity

99.77

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

ClC(N=C1NC2CCCC2)=NC3=C1N=CN3[C@H]4[C@H](O)[C@H](O)[C@@H](CO)O4

Molecular Formula

C15H20ClN5O4

Molecular Weight

369.80

Precautions

H302, H315, H319, H335

References & Citations

[1]Man S, et al. Potential and promising anticancer drugs from adenosine and its analogs. Drug Discov Today. 2021 Jun;26 (6) :1490-1500.|[2]Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18 (23) :3373-88.|[3]Lohse MJ, et al. 2-Chloro-N6-cyclopentyladenosine: a highly selective agonist at A1 adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol. 1988 Jun;337 (6) :687-9.